In vivo target-screening for age-related disease mechanisms
PrimaryArrive Bio's stated causal theory is that screening biological targets directly in vivo can reveal targets whose modulation affects age-related disease biology more reliably than approaches that rely only on in vitro or computational evidence. The intervention is not a single drug program but a discovery platform: identify targets in living systems, then prioritize those whose perturbation produces disease-relevant biological changes. Testable predictions are that in vivo screens will identify targets whose modulation changes phenotypes or biomarkers linked to age-related disease, and that prioritized targets will reproduce their effects across follow-up models better than targets selected from less physiologic screening systems.
Popperian evaluation
The premise is biologically credible: living systems preserve tissue context, immune signaling, metabolism, pharmacodynamic feedback, and organism-level compensation that cell culture and computational screens can miss. The weak spot is scope. The theory says in vivo screening should be more reliable for age-related disease mechanisms, but the supplied evidence gives only one directly relevant HTT pilot citation, with no abstract, year, model details, endpoints, or replication data. Plausible, yes. Proven here, no.
Supporting evidence: The core premise states that in vivo screening can reveal target effects missed by in vitro or computational systems.; The reasoning graph includes a specific assumption that living systems preserve physiologic context needed for disease-relevant target effects.; The platform logic is internally consistent: perturb targets in living systems, then prioritize targets that change disease-linked phenotypes or biomarkers.
Counter evidence: The HTT pilot study is cited as the main support, but the supplied metadata lacks an abstract, publication year, journal, and endpoint detail.; Most supplied publications do not directly support age-related in vivo target-screening: they cover antiviral nomenclature, pathology AI validation, or in vitro tumor models.; The theory does not specify which age-related diseases, which organisms, which perturbation methods, or which biomarkers count as decisive.
The theory explains why some targets selected in simplified systems might fail later: the screen missed biology that only appears in a living organism. That is a useful explanation, but the supplied evidence does not yet show that Arrive Bio's in vivo prioritization explains actual target success better than alternatives such as better assay design, larger datasets, improved disease models, or simple selection bias. Right now it is a good causal hypothesis with thin observed backing.
Supporting evidence: The theory directly accounts for mis-ranked targets by pointing to missing disease-relevant in vivo biology in less physiologic systems.; It predicts better reproduction of effects across follow-up models for targets prioritized from in vivo perturbation data.; The platform framing fits a discovery problem rather than a single-drug mechanism, which makes the theory broad enough to explain target-ranking behavior.
Counter evidence: No supplied evidence shows that in vivo-selected targets outperform targets selected by in vitro or computational approaches.; The HTT pilot study may support feasibility, but the provided metadata does not show disease relevance, comparator performance, or reproducibility.; The remaining publications are largely off-target for this theory, so they do not help distinguish this explanation from ordinary model-selection or assay-quality explanations.
This theory can be tested cleanly. Run matched target screens in vivo and in less physiologic systems, predefine disease-linked phenotypes or biomarkers, then compare hit reproducibility across follow-up models. The theory loses if in vivo-selected targets do not reproduce better, or if they perform no better than targets chosen from cell-based or computational screens. The missing piece is operational detail: without named models, thresholds, and endpoints, the prediction is testable in principle but still loose in practice.
Supporting evidence: The theory predicts that in vivo screens will identify targets whose modulation changes phenotypes or biomarkers linked to age-related disease.; It also predicts that prioritized targets will reproduce their effects across follow-up models better than targets selected from less physiologic systems.; The claim allows a direct comparator design: in vivo-derived target lists versus in vitro or computationally derived target lists.
Counter evidence: The dossier does not define a minimum effect size, replication threshold, disease model, organism, perturbation method, or biomarker panel.; The phrase age-related disease biology is broad enough that weak biomarker movement could be over-read unless endpoints are locked before testing.; No supplied study design shows that these predictions have already been tested head-to-head.
Reasoning tree
Public endorsements
The record shows that Anuj Gaggar is Arrive Bio's Co-Founder and CEO, and that he appeared on a public longevity panel. It does not include any quoted statement from him about Arrive Bio's theory that in vivo target screening is a better way to find age-related disease mechanisms. On this evidence, he is publicly tied to the company but stays silent on the specific theory.
Evidence publication IDs: e134f078-904e-4a8e-83c5-ef835b490bdb
The record places Evan Szu on Arrive Bio's website as a speaker at the Singapore Academy of Sciences, but it gives no quote, no paraphrased claim, and no statement from him about Arrive's in vivo target-screening theory. On this evidence, he is publicly present around the company, but silent on the theory itself.
Evidence publication IDs: db8ca908-e732-439d-85a4-bf4333b84ce6, 65ff539a-789d-4287-89da-0e5cb07dfe4b, 72365e3a-bd93-4f54-8c39-3bd30a46ed7d